DDIT3 and diffuse large B-cell lymphoma: Since development of R-CHOP for newly diagnosed diffuse large B-cell lymphoma (DLBCL) [1, 2], many attempts have been made to improve first-line therapy including studies which changed the timing/dosing of rituximab [3–5], substituted obinutuzumab for rituximab [6], added etoposide to CHOP in R-CHOEP [7], or changed to infusional regimens like dose-adjusted EPOCH-R [8].